is the enzyme responsible for the breakdown of heme-generating carbon monoxide (CO) and biliverdin in this process. HO-2 is the constitutively expressed isoform in most tissues, such as the kidney and vasculature. CO generated by HO is believed to be an important vasodilator in the renal circulation along with another gas, nitric oxide (NO). To determine the importance of HO-2 in the regulation of blood pressure and renal blood flow (RBF), we treated HO-2 knockout (KO) mice chronically with either ANG II or N G -nitroarginine methyl ester (L-NAME). Basal blood pressures were not different between wildtype (WT), heterozygous (HET), or KO mice and averaged 113 Ϯ 3 vs. 115 Ϯ 2 vs. 116 Ϯ 2 mmHg. Similar increases in blood pressure to chronic ANG II as well as L-NAME treatment were observed in all groups with blood pressures increasing an average of 30 mmHg in response to ANG II and 15 mmHg in response to L-NAME. Basal RBFs were not different between the groups averaging 6.0 Ϯ 0.5 (n ϭ 6) vs. 4.8 Ϯ 0.6 (n ϭ 10) vs. 5.8 Ϯ 0.7 (n ϭ 6) ml ⅐ min Ϫ1 ⅐ g Ϫ1 kidney weight in WT, HET, and KO mice. HO-2 KO and HET mice exhibited an attenuated decrease in RBF in response to acute administration of ANG II, while no differences were observed with L-NAME. Our data indicate that blood pressure and RBF responses to increased ANG II or inhibition of nitric oxide are not significantly enhanced in HO-2 KO mice. angiotensin II; nitric oxide; L-NAME; heme oxygenase-1; carbon monoxide; renal vascular resistance; gene targeting HEME OXYGENASE (HO) is the enzyme that is responsible for the breakdown of heme into equimolar amounts of ferrous iron, carbon monoxide (CO), and biliverdin. Two main isoforms of HO have been described: HO-1 and HO-2. HO-1, also known as heat shock protein 32, is the inducible isoform. HO-1 can be increased by a vast array of physiological and pathophysiological stimuli including: inflammation, proinflammatory cytokines, shear stress, hypoxia, hyperoxia, and other oxidants (1). HO-2 is the constitutively expressed isoform with high levels of expression in many organs especially the brain and testes (26).
HEME OXYGENASE (HO) is the enzyme that is responsible for the breakdown of heme into equimolar amounts of ferrous iron, carbon monoxide (CO), and biliverdin. Two main isoforms of HO have been described: HO-1 and HO-2. HO-1, also known as heat shock protein 32, is the inducible isoform. HO-1 can be increased by a vast array of physiological and pathophysiological stimuli including: inflammation, proinflammatory cytokines, shear stress, hypoxia, hyperoxia, and other oxidants (1) . HO-2 is the constitutively expressed isoform with high levels of expression in many organs especially the brain and testes (26) .
HO-2 is the main isoform expressed in the vasculature under basal conditions (10, 25) . However, HO-1 can be induced in vascular smooth muscle cells by several stimuli including metals, hypoxia, and endotoxemia (14, 15, 24) . CO derived from the actions of HO causes vasodilatation in several tissues, including the brain, heart, lung, and kidney (3, 13, 16, 27) . In the renal vasculature, CO serves to buffer against ANG II and phenylephrine-induced vasoconstriction and protects the renal vasculature from excessive vasoconstriction in the absence of nitric oxide (NO) generation (2, 9) .
HO-2 gene knockout mice have been generated and have revealed an important role for HO-2 in neural signaling, cytoprotection of neurons, and regulation of cerebral blood flow (4, 18, 26) . These mice have also been used to demonstrate that HO-2 can protect the kidney from oxidative stressinduced renal pathology in diabetes (6) . Previous studies have indicated an important role for HO in protecting the renal vasculature from excessive vasoconstriction due to increases in ANG II or inhibition of NO (2, 9) . In light of these findings, we hypothesized that loss of the constitutively active isoform of HO found in the vasculature (HO-2), would result in an exaggerated blood pressure response to chronic L-NAME or ANG II treatment as well as a greater decrease in renal blood flow (RBF) in response to acute administration of these compounds. This hypothesis was tested using HO-2 knockout mice.
METHODS

Animals.
Experiments were performed on 14-to 26-wk-old male and female HO-2 wild-type (WT), heterozygous (HET), and knockout (KO) mice generously supplied by Dr. Raymond F. Regan (Thomas Jefferson University, Philadelphia, PA). HO-2 KO mice were derived as initially described by Poss et al. (17) and maintained on a mixed C57Bl/6 ϫ 129/Sv background by breeding of HET ϫ HET mice. HET mice were studied to determine whether there was a gene dosage effect on any observed phenotypic differences between WT and KO mice. The mice were fed a standard diet containing 0.29% NaCl and were provided water ad libitum. All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center and performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Male and female mice were randomly divided into treatment groups and were treated with N G -nitroarginine methyl ester (L-NAME) administered via the drinking water at 1 g/l with 0.1% sucrose to improve palatability. L-NAME was administered for 4 wk. Male mice were treated with ANG II (1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) delivered via an osmotic minipump implanted subcutaneously for 12 days.
Blood pressure. Blood pressure was directly measured via microrenathane catheters implanted into the carotid artery by using aseptic surgical technique as previously described (22) . This method is consistent with recommendations of the American Heart Association for measuring blood pressure in conscious animals (11) . Surgery was performed 5 days after implantation of the ANG II minipumps or 3 wk after starting L-NAME. The mice were allowed 2 days to recover from surgery and then mean arterial blood pressure (MAP) was recorded from conscious, freely moving mice 3 h/day for five consecutive days. Blood pressures are presented as the average daily pressure over the entire 5-day recording period.
RBF. RBF was measured in separate groups of male mice by using a perivascular flow probe (model 0.5 PSB; Transonic, Ithaca, NY) positioned on the right renal artery in anesthetized mice as previously described (19) . RBF was measured using a TS420 perivascular flow meter and recorded, along with arterial pressure, with a computerized chart recorder (PowerLab; ADInstruments). Baseline MAP and RBF were recorded for 15-20 min after which time mice received a bolus intravenous infusion of either ANG II (1 or 10 ng) or L-NAME (50 mg/kg) and MAP and RBF were measured for 10 min. All infusions were given in a 10-l volume and the order was randomized between animals. Basal RBF values are reported as milliliters per minute per kidney weight in grams. Renal vascular resistance (RVR) was calculated from pressure and flow data and reported as resistance units (RU ϭ mmHg/ml/min/g).
HO assay. HO assay was performed on lysates prepared from the aorta and whole kidney as previously described (22) . The protein concentration was measured using a Bio-Rad (Hercules, CA) protein assay with BSA standards. Reactions were carried out in a 1.2 ml containing: 2 mM glucose-6-phosphate, 0.2 units glucose-6-phosphate dehydrogenase, 0.8 mM NADPH, 20 M hemin, and 0.5 mg of lysate. The reactions were incubated for 1 h at 37°C in the dark. The formed bilirubin was extracted with chloroform, and the change in optical density (⌬OD) at 464 -530 nm was measured using an extinction coefficient of 40 mM/cm for bilirubin. HO activity was expressed as picomoles of bilirubin formed per hour per milligram of microsomal protein.
Western blot analysis. Western blots for HO proteins were performed on lysates prepared from the aorta and whole kidney. Samples of 50 g of protein were boiled in Laemmli sample buffer (Bio-Rad) for 5 min, electrophoresed on 7.5% SDS-polyacrylamide gels, and blotted onto nitrocellulose membrane. Membranes were blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE) for 2 h at room temperature and then incubated with either rabbit anti-HO-2 polyclonal antibody (StressGen, Vancouver, Canada 1:2,000) and mouse anti-␤-actin antibody (Gentest, 1:5,000) or mouse anti-HO-1 polyclonal antibody (StressGen, Vancouver, Canada 1:2,000) and rabbit anti-␤-actin antibody (Gentest, 1:5,000) overnight at 4°C. The membranes were then incubated with Alex Fluor 680 goat anti-rabbit IgG (Molecular Probes) and IRDye 800 goat anti-mouse IgG (Rockland, Gilbertsville, PA) for 1 h at room temperature. The membranes were then visualized using an Odyssey infrared imager (Li-COR), which allows for simultaneous detection of two proteins. Densitometry analysis was performed using Odyssey software (LI-COR).
Statistics. Mean values Ϯ SE are presented. Significant differences between mean values were determined using an unpaired t-test or by ANOVA followed by a post hoc test (Dunnett's). A P Ͻ 0.05 was considered to be significant.
RESULTS
Male HO-2 KO mice do not exhibit an exaggerated blood pressure response to ANG II or L-NAME. Basal blood pressure was not different between male WT, HET, and KO mice and averaged (113 Ϯ 3 vs. 115 Ϯ 2 vs. 116 Ϯ 2 mmHg, respectively) between the different genotypes ( Fig. 1) . ANG II treatment significantly increased blood pressure in all three genotypes to the same level, averaging 150 Ϯ 6 vs. 145 Ϯ 6 vs. 146 Ϯ 6 mmHg, respectively (Fig. 1) . Likewise, L-NAME treatment resulted in a similar increase in blood pressure in all groups averaging 130 Ϯ 3 vs. 127 Ϯ 3 vs. 132 Ϯ 2 mmHg in WT, HET, and KO mice, respectively (Fig. 1) .
Enhanced cardiac hypertrophy in male HO-2 KO mice. Cardiac mass was examined in male HO-2 WT, HET, and KO mice as a ratio of heart weight to body wt. There were no differences in body weight between the different genotypes or in response to drug infusion. ANG II infusion resulted in significant increase in cardiac mass in all groups ( Fig. 2A) .
However, despite similar increases in blood pressure with L-NAME treatment, cardiac mass was significantly increased in HO-2 KO mice compared with control levels averaging 4.9 Ϯ 0.2 vs. 5.9 Ϯ 0.2 mg/g in each group, respectively. No differences in kidney mass were detected between the different genotypes or between the different treatment groups (Fig. 2B) .
Blood pressure and cardiac hypertrophy in female HO-2 KO mice. Basal blood pressure and blood pressure in response to chronic inhibition of NO with L-NAME was also examined in female HO-2 KO mice. No differences in basal blood pressure were observed among the different genotypes with blood pressure averaging 109 Ϯ 2 vs. 109 Ϯ 2 vs. 111 Ϯ 2 mmHg in WT, HET, and KO mice, respectively (Fig. 3A) . Chronic treatment with L-NAME resulted in a similarly significant increase in blood pressure in all groups with the pressures averaging 119 Ϯ 4 vs. 123 Ϯ 4 vs. 122 Ϯ 3 mmHg in each group, respectively (Fig. 3A) . Despite the similar increase in blood pressure in each group, cardiac mass in L-NAME-treated female mice was only increased in HO-2 KO mice from 4.9 Ϯ 0.3 to 6.3 Ϯ 0.4 mg/g (Fig. 3B) . No differences in kidney mass were detected between the different genotypes or after L-NAME treatment (Fig. 3C) . Given that we failed to observe any effect of HO-2 genotype on blood pressure in both male and female mice under basal conditions and in response to L-NAME treatment, we did not examine the effect of ANG II on blood pressure in female mice to minimize the number of animals used in the experimental protocol.
Loss of HO-2 does not alter RBF or RVR in male mice. Arterial pressure and RBF were measured in male HO-2 WT, HET, and KO mice under isoflurane anesthesia. Anesthetized blood pressure was not different between the groups (Fig. 4A) . Basal RBFs were also similar between the different genotypes and averaged 6 Ϯ 0.5 vs. 4.8 Ϯ 0.6 vs. 5.8 Ϯ 0.7 ml ⅐min Ϫ1 ⅐g kidney wt Ϫ1 , respectively (Fig. 4B) . Basal RVR was similar between the different genotypes averaging 15 Ϯ 1 vs. 23 Ϯ 4 vs. 17 Ϯ 2 RU in WT, HET, and KO mice, respectively (Fig. 4C) .
Loss of HO-2 does not enhance renal vasoconstriction to L-NAME but attenuates constriction to ANG II. Next, the acute effect of ANG II or L-NAME on RBF in anesthetized mice was examined. Bolus administration of ANG II at 1 ng caused a significantly greater decrease in RBF in WT mice compared with KO mice with RBF decreasing 47 Ϯ 10 vs. 35 Ϯ 12 vs. 18 Ϯ 8% (Fig. 5A) . Bolus administration of ANG II at 10 ng caused a significantly greater decrease in RBF in WT compared with both HET and KO mice with RBF, decreasing 83 Ϯ 8 vs. 41 Ϯ 18 and 46 Ϯ 18% in WT vs. HET vs. KO mice, respectively (Fig. 5B) . No difference in RBF in response to acute administration of L-NAME was detected between the genotypes (Fig. 5C) .
The change in RVR in response to each dose of ANG II was then determined. ANG II at 1 ng resulted in a similar increase in RVR in WT and HET mice; unexpectedly, the increase in RVR was significantly attenuated in HO-2 KO mice averaging 327 Ϯ 150 vs. 250 Ϯ 70 vs. 165 Ϯ 24% (Fig. 6A) . ANG II at 10 ng resulted in a greater increase in RVR in WT as opposed to both HET and KO mice averaging 788 Ϯ 230 vs. 543 Ϯ 105 vs. 249 Ϯ 75% (Fig. 6B) .
HO protein and activity in the aorta and kidney of HO-2 KO mice.
The levels of HO-1 and HO-2 protein were determined in the aorta of male mice. HO-2 protein was decreased in the aorta of HET and completely absent in the KO mice (Fig. 7A) . The levels of HO-1 protein were similar in the aorta of HO-2 WT, HET, and KO mice (Fig. 7A) . HO activity in the aorta was not different between WT and HET mice but was significantly decreased in KO mice averaging 706 Ϯ 35 vs. 579 Ϯ 59 vs. 231 Ϯ 37 pmoles bilirubin ⅐mg Ϫ1 ⅐h Ϫ1 in each group, respectively (Fig. 7B) .
In the kidney, HO-2 protein was decreased in HET and completely absent in the KO mice (Fig. 8A) . The levels of HO-1 protein were similar in the kidneys of WT, HET, and KO mice (Fig. 8A) . Basal HO activity in the kidney was significantly lower in HET and KO compared with WT mice averaging 40 Ϯ 6 vs. 31 Ϯ 3 vs. 28 Ϯ 3 pmoles bilirubin⅐mg Ϫ1 ⅐h Ϫ1 in WT vs. HET vs. KO (Fig. 8B ). There were no differences in kidney HO activity in response to ANG II treatment in any of the genotypes with HO activity averaging 33 Ϯ 6 vs. 24 Ϯ 6 vs. 24 Ϯ 5 pmoles bilirubin ⅐ mg Ϫ1 ⅐ h Ϫ1 in each group, respectively (Fig. 8B) . Renal HO activity was significantly decreased in HET and KO mice compared with WT mice in response to L-NAME treatment with HO activity averaging 47 Ϯ 3 vs. 33 Ϯ 4 vs. 22 Ϯ 5 pmol bilirubin ⅐ mg Ϫ1 ⅐ h Ϫ1 in WT vs. HET vs. KO, respectively (Fig. 8B) .
DISCUSSION
We report for the first time blood pressure and renal blow flow responses to ANG II infusion and NO blockade with L-NAME in HO-2 KO mice. Previous studies have demon- Fig. 2 . A: cardiac mass in male HO-2 WT, HET, and KO mice. Cardiac mass was measured as a ratio of heart weight to body weight. B: kidney mass in male WT, HET, and KO mice. Kidney mass was measured as a ratio of kidney weight to body weight. *P Ͻ 0.05 compared with corresponding control level. Fig. 3 . A: mean arterial blood pressure in female HO-2 WT, HET, and KO mice. Blood pressure was measured in conscious mice under control conditions and after chronic L-NAME administration as described in METH-ODS. *P Ͻ 0.05 compared with control. B: cardiac mass in female HO-2 WT, HET, and KO mice. Cardiac index was measured as a ratio of heart weight to body weight. *P Ͻ 0.05 compared with corresponding control level. C: kidney mass in female WT, HET, and KO mice. Kidney mass was measured as a ratio of kidney weight to body weight. strated an important role for vascular HO in the regulation of RBF in response to increased levels of ANG II and inhibition of NO (2, 9). Since HO-2 is the main isoform present in the vasculature (5, 25), we hypothesized that mice lacking this isoform would be more susceptible to the pressor actions of ANG II and L-NAME resulting in greater decreases in RBF and enhanced blood pressure response to chronic administration of these agents. However, this was not the case. The basal blood pressure, as well as the blood pressure response to chronic ANG II infusion or inhibition of NO with L-NAME, was equivalent between HO-2 WT and KO mice. While our blood pressure measurements are consistent with recent recommendations for acute measurement of blood pressure in conscious animals (11), we cannot make conclusions about the differences in 24-h blood pressure between HO-2 WT, HET, and KO mice. We did not observe any significant differences in basal RBF and RVR between HO-2 WT or KO mice.
RBF responses to acute administration of ANG II and L-NAME were also determined in HO-2 WT, HET, and KO mice. Interestingly, both HET and KO mice exhibited an attenuated RBF response to ANG II compared with WT mice. It is unlikely that HET or KO mice exhibit significant increases in plasma levels of ANG II, as baseline blood pressures were not different between the groups in either male or female mice. Fig. 4 . A: mean arterial blood pressure in anesthetized male HO-2 WT, HET, and KO mice. Blood pressure was measured in anesthetized mice as described in METHODS. B: basal renal blood flow (RBF) in anesthetized male WT, HET, and KO mice. RBF was measured in anesthetized mice as described in METHODS. C: renal vascular resistance (RVR) in WT, HET, and KO mice. RVR was calculated from pressure and flow data as described in METHODS. Likewise, no differences in basal RBF were detected between the different genotypes. We also failed to observe any differences in the attenuation of RBF by inhibition of NO with L-NAME between the different genotypes. This was particularly surprising given the important role of HO to maintain vascular diameter, which is unmasked by inhibition of NO in the renal vasculature (2) . Our results demonstrate a significant decrease in HO activity in the vasculature of HO-2 KO mice; however, we were still able to detect HO activity in the aorta of these mice albeit at a significantly lower level than observed in wild-type mice. The residual HO activity in the aorta is likely due to the presence of HO-1 protein, which was detected in the aorta of HO-2 KO mice. Thus, it is possible that HO-2 KO mice are capable of producing sufficient endogenous levels of CO required to regulate vascular tone in response to ANG II and blockade of NO. Another potential mechanism for the preservation of vascular tone in HO-2 KO mice is an upregulation in another vasodilatory system, such as prostacyclin (PGI2) or cytochrome P-450 epoxygenase; however, the role of these vasodilators in the preservation of RBF in HO-2 KO mice was not examined in the present study. Increased levels of these vasodilators could buffer against excessive vasoconstriction in response to ANG II or blockade of NO.
Renal HO activity was significantly decreased in both HET and KO mice compared with control mice under basal conditions and after chronic L-NAME treatment. Despite the lower HO activity, neither HET nor KO mice exhibited any difference in blood pressure compared with WT mice. This is surprising, because a previous report demonstrated that blockade of renal HO activity increases blood pressure under basal conditions and in response to increases in sodium intake (12) . However, while HO-2 KO mice exhibit lower total HO activity compared with WT mice, the levels of HO-1 protein in the kidney are not different between the groups. Thus, it is possible that a functional HO-1 in renal tubules is able to maintain appropriate salt and water balance in mice deficient in HO-2. This hypothesis is supported by a recent study in our laboratory that demonstrated renal-specific induction of HO-1 alone is able to significantly attenuate the development of ANG II hypertension (21) .
While we did not observe any significant differences in the blood pressure response to L-NAME between HO-2 WT and KO mice, the KO mice developed significantly more cardiac hypertrophy in response to the same increase in blood pressure compared with WT and HET mice. This was true in both male as well as female mice treated with L-NAME. This is the first evidence that suggests an important role for HO-2 in protecting the heart against hypertrophy in response to increases in blood pressure due to NO insufficiency. Several studies have reported that induction of HO-1 in the heart can protect against cardiac hypertrophy (7, 8, 20) . However, systemic induction of HO-1 utilized in these studies also results in a significant lowering of blood pressure, which may contribute to the anti-hypertrophic affect of HO-1 induction. One potential mechanism for the increased cardiac hypertrophy in the HO-2 KO mice could be increases in NADPH oxidase-dependent superoxide generation in the hearts of HO-2 KO mice. A recent study by Goodman et al., (6) reported an increase in superoxide generation in HO-2 KO mice upon induction of type I diabetes with streptozotocin. Increased generation of superoxide could act through apoptosis signal-regulating kinase, which has previously been demonstrated to mediate L-NAME-induced cardiac hypertrophy in the mouse (23) to increase cardiac hypertrophy in HO-2 KO mice. Future studies are needed to determine the potential contribution of increased cardiac superoxide generation to cardiac hypertrophy in L-NAME-treated HO-2 KO mice. 
